Journal of endocrinological investigation · 2026
NLRC5 p.Pro191Leu as a genetic susceptibility factor in anti-PIT-1 hypophysitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Urai Shin, Bando Hironori, Yamamoto Masaaki, Iguchi Genzo, Takahashi Yutaka
Аннотация
PURPOSE: Anti-PIT-1 hypophysitis is a rare T cell-mediated autoimmune pituitary disorder presenting as a paraneoplastic syndrome or after immune checkpoint inhibitor (ICI) therapy, and its predominance in Japan suggests an underlying genetic predisposition. The NLR family CARD domain containing 5 (NLRC5) encodes a key transcriptional regulator of major histocompatibility complex (MHC) class I, and its p.Pro191Leu missense variant is associated with ICI-related endocrinopathies and enhanced interferon-γ responses. Therefore, we examined whether NLRC5 p.Pro191Leu is enriched in anti-PIT-1 hypophysitis.
METHODS: We genotyped the NLRC5 p.Pro191Leu variant (c.572 C > T) in seven Japanese individuals with anti-PIT-1 hypophysitis for whom genomic DNA was available. The carrier frequency observed in this cohort was compared with ancestry-matched expectations from the Tohoku Medical Megabank 61KJPN Japanese reference panel using a prespecified one-sided exact binomial test. Sensitivity analyses included Mid-P adjustment, risk differences, and risk ratios.
RESULTS: Among seven genotyped Japanese individuals with anti-PIT-1 hypophysitis, five (71.4%) were carriers, exceeding the expected ancestry-matched frequency from the Japanese reference panel (expected carrier frequency 37.7%; exact p = 0.076; mid-P = 0.045). The effect sizes were risk difference + 0.337 and risk ratio 1.89.
CONCLUSION: This study provides suggestive evidence that the NLRC5 p.Pro191Leu variant may confer genetic susceptibility to anti-PIT-1 hypophysitis in the Japanese population, based on its enrichment relative to ancestry-matched reference panels. These findings, together with NLRC5's role as the master regulator of MHC class I expression, propose a novel and testable pathogenic model.
METHODS: We genotyped the NLRC5 p.Pro191Leu variant (c.572 C > T) in seven Japanese individuals with anti-PIT-1 hypophysitis for whom genomic DNA was available. The carrier frequency observed in this cohort was compared with ancestry-matched expectations from the Tohoku Medical Megabank 61KJPN Japanese reference panel using a prespecified one-sided exact binomial test. Sensitivity analyses included Mid-P adjustment, risk differences, and risk ratios.
RESULTS: Among seven genotyped Japanese individuals with anti-PIT-1 hypophysitis, five (71.4%) were carriers, exceeding the expected ancestry-matched frequency from the Japanese reference panel (expected carrier frequency 37.7%; exact p = 0.076; mid-P = 0.045). The effect sizes were risk difference + 0.337 and risk ratio 1.89.
CONCLUSION: This study provides suggestive evidence that the NLRC5 p.Pro191Leu variant may confer genetic susceptibility to anti-PIT-1 hypophysitis in the Japanese population, based on its enrichment relative to ancestry-matched reference panels. These findings, together with NLRC5's role as the master regulator of MHC class I expression, propose a novel and testable pathogenic model.